"Factor VIII" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Factor VIII of blood coagulation. Antihemophilic factor that is part of the factor VIII/von Willebrand factor complex. Factor VIII is produced in the liver and acts in the intrinsic pathway of blood coagulation. It serves as a cofactor in factor X activation and this action is markedly enhanced by small amounts of thrombin.
| Descriptor ID |
D005169
|
| MeSH Number(s) |
D12.776.124.125.350 D23.119.350
|
| Concept/Terms |
Factor VIII- Factor VIII
- Factor 8
- Coagulation Factor VIII
- Thromboplastinogen
- Blood Coagulation Factor VIII
- Factor Eight
Hyatt-C- Hyatt-C
- Hyatt C
- HyattC
- Hyate-C
- Hyate C
- HyateC
|
Below are MeSH descriptors whose meaning is more general than "Factor VIII".
Below are MeSH descriptors whose meaning is more specific than "Factor VIII".
This graph shows the total number of publications written about "Factor VIII" by people in this website by year, and whether "Factor VIII" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1993 | 1 | 0 | 1 |
| 1994 | 0 | 1 | 1 |
| 1996 | 2 | 0 | 2 |
| 1998 | 0 | 1 | 1 |
| 2002 | 0 | 1 | 1 |
| 2004 | 0 | 1 | 1 |
| 2006 | 1 | 0 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Factor VIII" by people in Profiles.
-
Lim MY, Nielsen B, Lee K, Kasthuri RS, Key NS, Ma AD. Rituximab as first-line treatment for the management of adult patients with non-severe hemophilia A and inhibitors. J Thromb Haemost. 2014 Jun; 12(6):897-901.
-
Onitilo AA, Skorupa A, Lal A, Ronish E, Mercier RJ, Islam R, Lazarchick J. Rituximab in the treatment of acquired factor VIII inhibitors. Thromb Haemost. 2006 Jul; 96(1):84-7.
-
McCall MM, Blackwell MM, Smyre JT, Sistino JJ, Acsell JR, Dorman BH, Bradley SM. Fresh frozen plasma in the pediatric pump prime: a prospective, randomized trial. Ann Thorac Surg. 2004 Mar; 77(3):983-7; discussion 987.
-
Hunt KJ, Pankow JS, Offenbacher S, Kritchevsky SB, Duncan BB, Shahar E, Sharrett AR, Heiss G. B-mode ultrasound-detected carotid artery lesions with and without acoustic shadowing and their association with markers of inflammation and endothelial activation: the atherosclerosis risk in communities study. Atherosclerosis. 2002 May; 162(1):145-55.
-
Ortel TL, Moore KD, Quinn-Allen MA, Okamura T, Sinclair AJ, Lazarchick J, Govindan R, Carmagnol F, Kane WH. Inhibitory anti-factor V antibodies bind to the factor V C2 domain and are associated with hemorrhagic manifestations. Blood. 1998 Jun 01; 91(11):4188-96.
-
Conroy JM, Fishman RL, Reeves ST, Pinosky ML, Lazarchick J. The effects of desmopressin and 6% hydroxyethyl starch on factor VIII:C. Anesth Analg. 1996 Oct; 83(4):804-7.
-
Slaughter TF, Greenberg CS. Practice guidelines and treatment of patients with von Willebrand's disease. Anesthesiology. 1996 Aug; 85(2):441-2.
-
Lazarchick J, Green C. Acquired von Willebrand's disease following bone marrow transplantation. Ann Clin Lab Sci. 1994 May-Jun; 24(3):211-5.
-
Slaughter TF, Mody EA, Oldham HN, Reves JG, O'Connor CM, Parker JK, Greenberg CS. Management of a patient with type IIC von Willebrand's disease during coronary artery bypass graft surgery. Anesthesiology. 1993 Jan; 78(1):195-7.
-
Lazarchick J, Ashby MA, Lazarchick JJ, Sens DA. Mechanism of factor VIII inactivation by human antibodies. IV. Antibody binding prevents factor VIII proteolysis by thrombin. Ann Clin Lab Sci. 1986 Nov-Dec; 16(6):497-501.